I’ve been waiting for 20 minutes when Jack Antonoff darts in, flustered, holding a bottle of sparkling water and a crumpled tote bag, from which he pulls out nasal spray and quickly spritzes it into ...

During the run-up to Election Day, Marya Hornbacher, a New York Times best-selling author and Walnut Creek native who travels the country writing about politics and culture, will profile residents of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Col. Anthony Bianchi was found guilty of one charge of failing to stop at a stop sign. He has submitted his retirement ...

The former commander of the U.S. Army Garrison West Point, Col. Anthony Bianchi, was found not guilty on charges related to ...

After hours: September 20 at 7:52 PM EDT Loading Chart for MRK ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...